论文部分内容阅读
目的评价卡培他宾对紫杉醇化疗失败的晚期乳腺癌近期疗效和不良反应。方法 41例晚期乳腺癌患者,给予卡培他宾治疗。按RECIST标准评价近期疗效,WHO标准评价不良反应。结果 41例患者获得完全缓解1例,部分缓解15例,稳定19例,进展6例,总有效率(完全缓解+部分缓解)为39.0%。主要不良反应为手足综合征、皮肤色素沉着、骨髓抑制及腹泻等,全组无治疗相关性死亡。结论卡培他宾对紫杉醇化疗失败的晚期乳腺癌,临床缓解率较高,不良反应轻,患者可以耐受。
Objective To evaluate the short-term curative effect and adverse reactions of capecitabine on advanced breast cancer with failed paclitaxel chemotherapy. Methods Forty-one patients with advanced breast cancer were treated with capecitabine. According to RECIST standard evaluation of recent efficacy, WHO standard evaluation of adverse reactions. Results In 41 patients, complete remission was achieved in 1 case, partial remission in 15 cases, stable in 19 cases and progression in 6 cases. The total effective rate (complete remission + partial remission) was 39.0%. The main adverse reactions were hand-foot syndrome, skin pigmentation, bone marrow suppression and diarrhea, the whole group without treatment-related deaths. Conclusions Capecitabine has a high clinical remission rate and mild adverse reactions in patients with advanced breast cancer that failed chemotherapy with paclitaxel. Patients can tolerate this.